Overview

Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

Status:
Not yet recruiting

Trial end date:
2024-09-14

Target enrollment:

Participant gender:

Summary

A Phase I/II, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination with Pembrolizumab in Advanced Solid Tumors

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

LaNova Medicines Limited

Treatments:

Antibodies